LBRX LBRX Formulation And CMC — Direct Research And Development Expenses

Similar metrics at other companies

MPLTChemistry Manufacturing And Controls Expenses — Research And Development Expense

$6.42M+62.2%

GERNChemistry, manufacturing, and control expenses — R&D

$600K-60.0%

AVTXReportable Segment — CMC expenses

$4.13M+108%

CSL

CSLCCM — Research and development expenses

$8.4M+3.7%

GERNResearch and clinical expenses — R&D

$13M-5.1%

RAPPOther Costs — Research And Development Expense

$1.97M+24.7%

Questions, answered.

What is LBRX's formulation and CMC — direct research and development expenses?

LBRX (LBRX) reported formulation and CMC — direct research and development expenses of $2.33M in Q1 2026.

How has LBRX's formulation and CMC — direct research and development expenses changed year-over-year?

LBRX's formulation and CMC — direct research and development expenses increased by 256.7% year-over-year, from $653K to $2.33M.

What does formulation and CMC — direct research and development expenses mean?

This metric represents the direct costs associated with the formulation development and Chemistry, Manufacturing, and Controls (CMC) activities for a specific drug candidate or therapeutic program. It captures the investment required to scale manufacturing processes, ensure product stability, and meet regulatory quality standards necessary for clinical trials and commercialization. Monitoring these expenses provides insight into the capital intensity and technical progress of a company's drug development pipeline.